Worth reading
71In focus
Scored from 2 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
900
¥ millionWording
Definitive
How definitive the wording is.Details of issuance or disposal
3rd to 5th Stock Acquisition Rights (with provisions for adjustment of the exercise price)
Amount of funds to be raised
Total funds raised: ¥2,025 million; estimated net proceeds: Not disclosed
Specific use of funds
Product procurement costsAmount ¥780 million
Personnel and other costs for existing employees engaged in development and customer supportAmount ¥600 million
Sales and sales promotion expensesAmount ¥520 million
Advertising expensesAmount ¥125 million
Terms of the stock acquisition rights
Exercise price
Only the fact that the Stock Acquisition Rights include provisions for adjustment of the exercise price is disclosed. Initial exercise price and adjustment floor: Not disclosed
Most recent equity financing
Issuance of the 3rd to 5th Stock Acquisition Rights (with provisions for adjustment of the exercise price), disclosed on 12 December 2025. Funds raised: ¥2,025 million
Impact on Business Performance
The impact on the Company’s results of the change in the specific use of the proceeds from these Stock Acquisition Rights has already been reflected in the earnings forecast dated 10 April 2026
| Item | Details |
|---|---|
| Type of issuance or disposal | 3rd to 5th Stock Acquisition Rights (with provisions for adjustment of the exercise price) |
| Amount of funds to be raised | Total funds raised: ¥2,025 million; estimated net proceeds: Not disclosed |
| Specific use of funds | Details Product procurement costs / Amount ¥780 million / Scheduled timing of expenditures Not disclosed, Details Personnel and other costs for existing employees engaged in development and customer support / Amount ¥600 million / Scheduled timing of expenditures Not disclosed, Details Sales and sales promotion expenses / Amount ¥520 million / Scheduled timing of expenditures Not disclosed, Details Advertising expenses / Amount ¥125 million / Scheduled timing of expenditures Not disclosed |
| Exercise price | Only the fact that the Stock Acquisition Rights include provisions for adjustment of the exercise price is disclosed. Initial exercise price and adjustment floor: Not disclosed |
| Most recent equity financing | Issuance of the 3rd to 5th Stock Acquisition Rights (with provisions for adjustment of the exercise price), disclosed on 12 December 2025. Funds raised: ¥2,025 million |
| Impact on Business Performance | The impact on the Company’s results of the change in the specific use of the proceeds from these Stock Acquisition Rights has already been reflected in the earnings forecast dated 10 April 2026 |
Items this document does not state (22)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Discussions aimed at making 話せるメディカル株式会社 a wholly owned subsidiary have ended, and the Company determined that there were no other candidates for which it was sufficiently likely that the funds could be allocated within the originally scheduled spending period. At the same time, in light of the expansion of the generative AI market, the Company determined that concentrating its management resources on the “Sovereign GaiXer” business would make the greatest contribution to increasing corporate value over the medium to long term.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.